Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Talazoparib

Review the clinical trials studying talazoparib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-16 of 16

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Location: 34 locations
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients with Advanced Solid Tumors, The ComBET Trial
Status: Active
Location: 33 locations
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Active
Location: 16 locations
Talazoparib for the Treatment of BRCA 1/2 Mutant Metastatic Breast Cancer
Status: Active
Location: 7 locations
Talazoparib with Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer, TRIPLE-PRO Trial
Status: Active
Location: 5 locations
Measuring the Effects of Talazoparib in Patients with Advanced Cancer and DNA Repair Variations
Status: Active
Location: 3 locations
Talazoparib and Radiation Therapy in Treating Patients with Locally Recurrent Gynecologic and Prostate Cancers
Status: Active
Location: 3 locations
Talazoparib in Combination with Pacritinib for the Treatment of Patients with Myeloproliferative Neoplasms Unresponsive to Frontline JAK2 Inhibition
Status: Active
Location: 2 locations
ZEN003694 Combined with Talazoparib for the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Enzalutamide and Talazoparib with Androgen Deprivation Therapy for the Treatment of Patients with Prostate Cancer that is Metastatic to the Lymph Nodes at Diagnosis
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of ZN-c3 in Participants With Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Telmisartan Alone or Combined with Selected Standard of Care Therapy for the Treatment of Prostate Cancer
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Talazoparib in Treating Patients with Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Evaluation of Circulating Tumor DNA Levels as a Predictive Marker for Switching Treatment Earlier in Patients with Metastatic Breast Cancer
Status: Temporarily Closed to Accrual
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Onivyde in Combination with Talazoparib or Temozolomide for the Treatment of Recurrent or Refractory Solid Tumors and Ewing Sarcoma
Status: Temporarily Closed to Accrual
Location: 6 locations
Implantable Microdevice for the Evaluation of Drug Response in Patients with Prostate Cancer
Status: Active
Location: 2 locations